Advertisement

Pathophysiology of Overactive Bladder

  • Márcio Augusto Averbeck
  • Howard B. Goldman
Chapter

Abstract

Overactive bladder (OAB) syndrome is defined by the International Continence Society as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathologies. Various theories have been proposed to elucidate the pathophysiology of OAB. However, since the cause of OAB is often multifactorial and complex, there is not a unique and widely accepted pathophysiological mechanism to explain this syndrome. This chapter aims to describe the various hypotheses, which may help in understanding the origin of OAB symptoms.

Keywords

Overactive bladder Urgency Urgency urinary incontinence Urinary bladder Detrusor overactivity Pathophysiology Myogenic Neurogenic Afferent Urothelium Microbiome Environmental factors Neuromodulation 

References

  1. 1.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350(8):786–99.PubMedCrossRefGoogle Scholar
  3. 3.
    Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175(1):191–4. discussion 4–5PubMedCrossRefGoogle Scholar
  4. 4.
    Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin North Am. 2006;33(4):491–501. ixPubMedCrossRefGoogle Scholar
  5. 5.
    Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174(5):1862–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Turner WH, Brading AF. Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol Ther. 1997;75(2):77–110.PubMedCrossRefGoogle Scholar
  8. 8.
    Andersson KE. Treatment-resistant detrusor overactivity – underlying pharmacology and potential mechanisms. Int J Clin Pract Suppl. 2006;60(151):8–16.CrossRefGoogle Scholar
  9. 9.
    Drake MJ, Harvey IJ, Gillespie JI, Van Duyl WA. Localized contractions in the normal human bladder and in urinary urgency. BJU Int. 2005;95(7):1002–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Keay SK, Birder LA, Chai TC. Evidence for bladder urothelial pathophysiology in functional bladder disorders. Biomed Res Int. 2014;2014:865463.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    de Groat WC, Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol. 2009;194:91–138.CrossRefGoogle Scholar
  12. 12.
    Guan NN, Gustafsson LE, Svennersten K. Inhibitory effects of urothelium-related factors. Basic Clin Pharmacol Toxicol. 2017;121(4):220–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Stenqvist J, Winder M, Carlsson T, Aronsson P, Tobin G. Urothelial acetylcholine involvement in ATP-induced contractile responses of the rat urinary bladder. Eur J Pharmacol. 2017;809:253–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Chai TC, Gray ML, Steers WD. The incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity. J Urol. 1998;160(1):34–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Gill BC, Pizarro-Berdichevsky J, Bhattacharyya PK, Brink TS, Marks BK, Quirouet A, et al. Real-time changes in brain activity during sacral neuromodulation for overactive bladder. J Urol. 2017;198(6):1379–85.PubMedCrossRefGoogle Scholar
  16. 16.
    Chacko S, Cortes E, Drake MJ, Fry CH. Does altered myogenic activity contribute to OAB symptoms from detrusor overactivity? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):577–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Drake MJ, Hedlund P, Harvey IJ, Pandita RK, Andersson KE, Gillespie JI. Partial outlet obstruction enhances modular autonomous activity in the isolated rat bladder. J Urol. 2003;170(1):276–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Sadananda P, Drake MJ, Paton JF, Pickering AE. An exploration of the control of micturition using a novel in situ arterially perfused rat preparation. Front Neurosci. 2011;5:62.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Fry CH, Sui GP, Severs NJ, Wu C. Spontaneous activity and electrical coupling in human detrusor smooth muscle: implications for detrusor overactivity? Urology. 2004;63(3 Suppl 1):3–10.PubMedCrossRefGoogle Scholar
  20. 20.
    Kanai A, Roppolo J, Ikeda Y, Zabbarova I, Tai C, Birder L, et al. Origin of spontaneous activity in neonatal and adult rat bladders and its enhancement by stretch and muscarinic agonists. Am J Physiol Renal Physiol. 2007;292(3):F1065–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653–80.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Fry CH, Vahabi B. The role of the mucosa in normal and abnormal bladder function. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3:57–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Olsen SM, Stover JD, Nagatomi J. Examining the role of mechanosensitive ion channels in pressure mechanotransduction in rat bladder urothelial cells. Ann Biomed Eng. 2011;39(2):688–97.PubMedCrossRefGoogle Scholar
  24. 24.
    Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, et al. Non-neuronal cholinergic system in human bladder urothelium. Urology. 2006;67(2):425–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Andersson KE, Persson K. Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles. World J Urol. 1994;12(5):274–80.PubMedGoogle Scholar
  26. 26.
    Winder M, Tobin G, Zupančič D, Romih R. Signalling molecules in the urothelium. Biomed Res Int. 2014;2014:297295.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    McCloskey KD. Bladder interstitial cells: an updated review of current knowledge. Acta Physiol (Oxf). 2013;207(1):7–15.CrossRefGoogle Scholar
  28. 28.
    Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder? Neurourol Urodyn. 2014;33(1):9–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Sun Y, Keay S, De Deyne PG, Chai TC. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol. 2001;166(5):1951–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol. 2005;174(5):2032–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Sakakibara R, Panicker J, Fowler CJ, Tateno F, Kishi M, Tsuyusaki Y, et al. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol. 2014;21(1):33–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Urinary function in elderly people with and without leukoaraiosis: relation to cognitive and gait function. J Neurol Neurosurg Psychiatry. 1999;67(5):658–60.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, et al. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur Urol. 2016;69(2):324–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Karstens L, Asquith M, Davin S, Stauffer P, Fair D, Gregory WT, et al. Does the urinary microbiome play a role in urgency urinary incontinence and its severity? Front Cell Infect Microbiol. 2016;6:78.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Sanford MT, Rodriguez LV. The role of environmental stress on lower urinary tract symptoms. Curr Opin Urol. 2017;27(3):268–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Melotti IGR, Juliato CRT, Coelho SCA, Lima M, Riccetto CLZ. Is there any difference between depression and anxiety in overactive bladder according to sex? A systematic review and meta-analysis. Int Neurourol J. 2017;21(3):204–11.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Maserejian NN, Kupelian V, Miyasato G, McVary KT, McKinlay JB. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol. 2012;188(2):490–5.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Robinson D, Hanna-Mitchell A, Rantell A, Thiagamoorthy G, Cardozo L. Are we justified in suggesting change to caffeine, alcohol, and carbonated drink intake in lower urinary tract disease? Report from the ICI-RS 2015. Neurourol Urodyn. 2017;36(4):876–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Daher JP, Gover TD, Moreira TH, Lopes VG, Weinreich D. The identification of a caffeine-induced Ca2+ influx pathway in rat primary sensory neurons. Mol Cell Biochem. 2009;327(1–2):15–9.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG. 2003;110(3):247–54.PubMedCrossRefGoogle Scholar
  41. 41.
    Jura YH, Townsend MK, Curhan GC, Resnick NM, Grodstein F. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol. 2011;185(5):1775–80.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs. 2002;11(8):560–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Echeverri D, Montes FR, Cabrera M, Galán A, Prieto A. Caffeine’s vascular mechanisms of action. Int J Vasc Med. 2010;2010:834060.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Bernstein AJ, Peters KM. Expanding indications for neuromodulation. Urol Clin North Am. 2005;32(1):59–63.PubMedCrossRefGoogle Scholar
  45. 45.
    Kessler TM, Wöllner J, Kozomara M, Mordasini L, Mehnert U. Sacral neuromodulation for neurogenic bladder dysfunction. Urologe A. 2012;51(2):179–83.PubMedCrossRefGoogle Scholar
  46. 46.
    van der Pal F, Heesakkers JP, Bemelmans BL. Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction. Curr Opin Urol. 2006;16(4):261–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromodulation. 2000;3(1):16–26.PubMedCrossRefGoogle Scholar
  48. 48.
    Zhang F, Zhao S, Shen B, Wang J, Nelson DE, Roppolo JR, et al. Neural pathways involved in sacral neuromodulation of reflex bladder activity in cats. Am J Physiol Renal Physiol. 2013;304(6):F710–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Su X, Nickles A, Nelson DE. Optimization of neuromodulation for bladder control in a rat cystitis model. Neuromodulation. 2016;19(1):101–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Snellings AE, Grill WM. Effects of stimulation site and stimulation parameters on bladder inhibition by electrical nerve stimulation. BJU Int. 2012;110(1):136–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Peters KM, Shen L, McGuire M. Effect of sacral neuromodulation rate on overactive bladder symptoms: a randomized crossover feasibility study. Low Urin Tract Symptoms. 2013;5(3):129–33.PubMedCrossRefGoogle Scholar
  52. 52.
    van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as “Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus” in Z Hyg Infekt. 1897;26:1–56. Rev Infect Dis. 1979;1(4):701–19.Google Scholar
  53. 53.
    Kuo YC, Kuo HC. Botulinum toxin injection for lower urinary tract dysfunction. Int J Urol. 2013;20(1):40–55.PubMedCrossRefGoogle Scholar
  54. 54.
    Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Soljanik I. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review. Drugs. 2013;73(10):1055–66.PubMedCrossRefGoogle Scholar
  56. 56.
    Jo JK, Kim KN, Kim DW, Kim YT, Kim JY. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. World J Urol. 2018;36(2):305–17. https://doi.org/10.1007/s00345-017-2121-6. Epub 2017 Nov 9.PubMedCrossRefGoogle Scholar
  57. 57.
    Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med. 2013;36(5):402–19.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Meier T, Wallace BG. Formation of the neuromuscular junction: molecules and mechanisms. BioEssays. 1998;20(10):819–29.PubMedCrossRefGoogle Scholar
  59. 59.
    Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, et al. Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol. 2008;5(6):319–28.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Kanagarajah P, Ayyathurai R, Caruso DJ, Gomez C, Gousse AE. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. Int Urol Nephrol. 2012;44(1):91–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology. 2005;66(1):208–12.PubMedCrossRefGoogle Scholar
  62. 62.
    Yokokawa R, Akino H, Ito H, Zha X, Yokoyama O. Nerve growth factor release from the urothelium increases via activation of bladder C-fiber in rats with cerebral infarction. Neurourol Urodyn. 2017;36(6):1448–55.PubMedCrossRefGoogle Scholar
  63. 63.
    Yokoyama T, Chancellor MB, Oguma K, Yamamoto Y, Suzuki T, Kumon H, et al. Botulinum toxin type A for the treatment of lower urinary tract disorders. Int J Urol. 2012;19(3):202–15.PubMedCrossRefGoogle Scholar
  64. 64.
    Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174(3):977–82; discussion 82–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Márcio Augusto Averbeck
    • 1
  • Howard B. Goldman
    • 2
  1. 1.Neuro-Urology Coordinator, Videourodynamics Unit, Department of UrologyMoinhos de Vento HospitalPorto AlegreBrazil
  2. 2.Glickman Urologic and Kidney InstituteCleveland ClinicClevelandUSA

Personalised recommendations